BridgeBio Pharma, Inc.
76.08USD
+1.3200 (+1.77%)
Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.
| Period | Consensus EPS | 90 days ago | Revisions up (30d) | Revisions down (30d) |
|---|---|---|---|---|
| Current quarter | $-0.63▼ | $-0.48 | 0 | 6 |
| Next quarter | $-0.44▼ | $-0.31 | 1 | 5 |
| Current year | $-2.58▼ | $-2.22 | 0 | 7 |
| Next year | $0.03▼ | $0.5 | 2 | 5 |
Beat in 1 of the last 4
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| 2026-06-30 | $-0.58 | $-0.78 | -0.20 (-33.9%) |
| 2026-03-31 | $-0.62 | $-0.84 | -0.22 (-36.2%) |
| 2025-12-31 | $-0.62 | $-0.94 | -0.32 (-50.6%) |
| 2025-09-30 | $-0.78 | $-0.72 | +0.06 (+7.7%) |
178 ratings from 31 firms
Ratings are attributed to the research firm, not to individual analysts. See every ticker.
| Firm | Action | Rating | Price Target | Date |
|---|---|---|---|---|
| HC Wainwright & Co. | Reiterated | Buy | $120 | Sep 2, 2026 |
| Mizuho | Maintained | Outperform | $96 $110 | Sep 1, 2026 |
| Truist Securities | Maintained | Buy | $102 $107 | Aug 12, 2026 |
| Canaccord Genuity | Maintained | Buy | $104 $106 | Aug 12, 2026 |
| JP Morgan | Maintained | Overweight | $100 $111 | Aug 12, 2026 |
| B of A Securities | Maintained | Buy | $101 $104 | Aug 11, 2026 |
| TD Cowen | Maintained | Buy | $95 $110 | Aug 11, 2026 |
| Morgan Stanley | Maintained | Overweight | $98 $97 | Aug 11, 2026 |
| Piper Sandler | Maintained | Overweight | $111 $115 | Aug 11, 2026 |
| Wells Fargo | Maintained | Overweight | $98 $102 | Aug 11, 2026 |
| Citigroup | Maintained | Neutral | $82 $93 | Jul 16, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $110 $120 | Jul 13, 2026 |
| Mizuho | Maintained | Outperform | $106 $96 | Jun 16, 2026 |
| Canaccord Genuity | Initiated | Buy | $104 | Jun 3, 2026 |
| Morgan Stanley | Maintained | Overweight | $94 $98 | May 28, 2026 |
| HC Wainwright & Co. | Reiterated | Buy | $110 | May 28, 2026 |
| Raymond James | Downgraded from Outperform | Market Perform | — | May 26, 2026 |
| Citigroup | Initiated | Neutral | $82 | May 19, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $100 $110 | May 11, 2026 |
| Evercore ISI Group | Maintained | Outperform | $125 $130 | May 8, 2026 |
| Truist Securities | Maintained | Buy | $95 $102 | Apr 29, 2026 |
| HC Wainwright & Co. | Reiterated | Buy | $100 | Apr 29, 2026 |
| Mizuho | Reiterated | Outperform | $106 | Apr 28, 2026 |
| HC Wainwright & Co. | Reiterated | Buy | $100 | Apr 27, 2026 |
| RBC Capital | Initiated | Outperform | $100 | Apr 9, 2026 |
139 filings from 19 insiders · 23 buy / 16 sell over 6m
Officers and directors of BBIO, from the last two years of filings. Grants, gifts and option exercises are shown but not colour-coded — they are compensation, not a view on the price.
| Insider | Action | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| KUMAR NEILChief Executive Officer | Sell | 45.0k | $81.15 | $3.73M | Aug 19, 2026 |
| KUMAR NEILChief Executive Officer | Other | 71.2k | — | — | Aug 14, 2026 |
| APULI MARICELOfficer | Sell | 2.0k | $80.06 | $160k | Jul 30, 2026 |
| ELLIS ANDREADirector | Sell | 17.2k | $84.00 | $1.44M | Jul 9, 2026 |
| COOK JENNIFER EDirector | Sell | 148.6k | $84.00 | $13.16M | Jul 9, 2026 |
| ELLIS ANDREADirector | Exercise | 17.2k | $16.75 | $288k | Jul 9, 2026 |
| COOK JENNIFER EDirector | Exercise | 148.6k | $8.45 | $3.71M | Jul 9, 2026 |
| COOK JENNIFER EDirector | Sell | 39.4k | $68.57 | $2.75M | Jun 24, 2026 |
| COOK JENNIFER EDirector | Exercise | 37.2k | $8.45 | $457k | Jun 24, 2026 |
| VALANTINE HANNAH A.Director | Sell | 5.0k | $68.00 | $342k | Jun 23, 2026 |
| VALANTINE HANNAH A.Director | Exercise | 2.8k | $41.73 | $117k | Jun 22, 2026 |
| HOMCY CHARLES JDirector | Grant | 4.0k | — | — | Jun 22, 2026 |
| MCCORMICK FRANK P. PH.D.Director | Grant | 4.0k | — | — | Jun 22, 2026 |
| DANIELS RONALD JDirector | Grant | 4.0k | — | — | Jun 22, 2026 |
| MOMTAZEE JAMES CDirector | Grant | 4.0k | — | — | Jun 22, 2026 |
| SATVAT ALI JDirector | Grant | 4.0k | — | — | Jun 22, 2026 |
| AGUIAR ERICDirector | Grant | 4.0k | — | — | Jun 22, 2026 |
| DACHILLE DOUGLAS A.Director | Grant | 4.0k | — | — | Jun 22, 2026 |
| LO ANDREW W.Director | Grant | 4.0k | — | — | Jun 22, 2026 |
| COOK JENNIFER EDirector | Grant | 4.0k | — | — | Jun 22, 2026 |
No analyst notes on BBIO yet.
Analyst Ratings
21 analysts covering
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Consensus |
|---|---|---|---|---|---|---|
| Current | 5 | 14 | 3 | 0 | 0 | Buy1.91 |
| 1 mo ago | 5 | 14 | 3 | 0 | 0 | Buy1.91 |
| 2 mo ago | 6 | 14 | 2 | 0 | 0 | Buy1.82 |
| 3 mo ago | 6 | 16 | 2 | 0 | 0 | Buy1.83 |